## TMO: Thermo Fisher Scientific Inc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.8% below STRENGTH zone (3.0-6.0%); PEG 1.95 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($537.55)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Baker Avenue Asset Management LP Boosts Stake in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251208T084201 | Somewhat-Bullish | Relevance: 99%
-  Baker Avenue Asset Management LP increased its stake in Thermo Fisher Scientific Inc. by 13.3%, now holding 23,034 shares valued at $9.34 million. This comes as institutional investors collectively own about 89.23% of the company, which recently reported strong quarterly earnings exceeding estimates and announced a $5.0 billion share buyback and a $0.43 quarterly dividend. Despite some insider selling, analysts maintain a "Moderate Buy" rating for Thermo Fisher Scientific.

**2. Temasek Holdings Private Ltd Trims Stake in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251208T125043 | Somewhat-Bullish | Relevance: 99%
-  Temasek Holdings Private Ltd reduced its stake in Thermo Fisher Scientific Inc. by 9.1% during the second quarter, now owning 0.30% of the company's stock valued at $463.64 million. Despite this, other institutional investors have increased their holdings, and analysts maintain a "Moderate Buy" rating for TMO with a consensus price target of $609.38. Insiders have also sold shares, but the company recently announced a quarterly dividend and a $5 billion share repurchase program.

**3. Axa S.A. Lowers Stake in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251209T083456 | Somewhat-Bullish | Relevance: 98%
-  Axa S.A. has reduced its stake in Thermo Fisher Scientific Inc. by 15.9% during the second quarter, selling 82,824 shares and now owning 437,727 shares worth $177,481,000. Meanwhile, other institutional investors like Norges Bank and Soundwatch Capital LLC have acquired significant new stakes in the medical research company. Thermo Fisher Scientific recently reported strong earnings, beating analyst estimates, and announced a stock repurchase program of $5.00 billion, along with a quarterly dividend of $0.43 per share.

**4. Vega Investment Solutions Sells 11,414 Shares of Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251208T130904 | Somewhat-Bullish | Relevance: 98%
- Vega Investment Solutions significantly reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by selling 11,414 shares, retaining only 260 shares. This comes amidst substantial insider selling, with CEO Marc N. Casper and EVP Frederick M. Lowery offloading shares worth millions. Despite these sales, Thermo Fisher Scientific reported strong Q3 earnings, beating expectations, and announced a $5 billion share buyback program and a quarterly dividend.

**5. Thermo Fisher Expands BioProcessing in Asia**
- Source: Powder & Bulk Solids | 20251210T014456 | Bullish | Relevance: 98%
-  Thermo Fisher Scientific is expanding its bioprocessing capabilities across Asia to support the region's growing biopharmaceutical industry. The company is opening a new Bioprocess Design Center in Hyderabad, India, and has expanded existing centers in Incheon, Korea, and Singapore. This strategic network aims to enhance speed, efficiency, and sustainability in biomanufacturing while providing localized support and access to advanced technologies.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $685 | $0 | 0% |
| 2025-12-08 | Keybanc | $750 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $670 | $656 | +2% |
| 2025-12-01 | HSBC | $670 | $550 | +22% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-08 | Keybanc | up | Overweight |
| 2025-12-02 | Morgan Stanley | main | Overweight |
| 2025-12-01 | HSBC | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 6 ($1.76M) |
| Sells | 14 ($41.68M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.0% (+0.2%)
- Blackrock Inc.: 7.9% (+8.4%)
- State Street Corpora: 4.4% (-0.6%)
- JPMORGAN CHASE & CO: 3.9% (+58.9%)
- Morgan Stanley: 3.4% (-1.2%)

### Key Risks

1. Heavy insider selling: $42M sold (14 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.95 elevated, pricing in significant growth expectations. Forward P/E 22.8x stretched relative to 8% growth. Balance sheet: $1.8B free cash flow. Analyst sentiment positive (2 raises, avg +12%). Insider selling cluster ($41.7M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $211.5B |
| Beta | 0.90 |
| 52W Range | $385.46 - $610.97 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.95 |
| Forward P/E | 22.8 |
| Current P/E | 24.8 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 weakening modestly (-0.9% over 5 days). Below STRENGTH zone by 6.8pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.17x) but short-term weakness (below SMA20). MACD histogram bearish (-4.20), momentum weakening. RSI neutral at 43.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.80% (CS: 16) | Weak |
| RSI_14 | 43.1 | Neutral |
| MACD Histogram | -4.20 | Bearish |
| vs SMA20 | 0.970x | Below |
| vs SMA50 | 1.004x | Above |
| vs SMA200 | 1.170x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $563.07
- **Stop Loss:** $537.55 (4.5% risk)
- **Target:** $588.59 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 11
- **Position Value:** $6,193.77
- **Portfolio %:** 6.19%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-01-29 (Est: $6.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.50 | $5.79 | +5.3% |
| 2025Q2 | $5.23 | $5.36 | +2.5% |
| 2025Q1 | $5.10 | $5.15 | +0.9% |
| 2024Q4 | $5.94 | $6.10 | +2.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*